call. everyone, and you, Thank Good welcome to morning, today's Gordon.
quarter in the year for to have progress Quoin's and whole. quite as Quoin. simply are opportunity a transformational the the to report truly was XXXX We throughout a on year pleased past
with the drug trial under During ever IND, we data application, investigational an U.S. open new that subjects in generated from the conducted released syndrome or Netherton clinical year, a first FDA. being
a a was overall significant a of clinical safety not end and complete of was was that just a signals community but positive milestone I'm as for to whole. data important say absence And Quoin, there Netherton also any crucially, and number initial This pleased encouraging whatsoever. across for a points. this
On clinical both and study. dose trials. the proposed and combination to strength data the to studies, ongoing once included open generated, initial IND had of a efficacy we of dosing blinded daily changing been protocol safety daily both this amendments our of These number to frequency from both that twice our of X% lower the the from increasing size the submitted eliminating
for being fully older. clinical again, will extremely a Those age FDA nonadult and another marks and And open Earlier is amendments into now eligibility been another for is we conducted Netherton were we amendment very proposed to that years occasion, older important studies milestone years by lowering the be This submitted the XX Netherton the year, to it as under XX clinical study for FDA. company. the the implemented. have yet time an this IND. subjects in community On tested that first our cleared this our and protocol recruitment from once
implementation made positive of protocol amendments by As from those just cleared on this on amendment basis March the of initial worth each were safety and efficacy strength also protocol mentioning of X, a announced was FDA. position latest for that the I data. It's discussed
to data took of greater of that. are more While The children the encouraging, could amendments lead that ongoing, this protocol always likelihood protocols approval especially and number a an believe, deliver into just subjects initial studies We noteworthy we eligible amend recruitment set as to was label. the our we when have faster even advantage significantly the should potential broad inclusion is of studies it and a generate new increases not of these data a robust temptation and there a to rate indeed with opportunity position while to positive with take is the overall.
the be treated the will accommodate will the children eligible them parents for Because participate caregivers patients to to therapy have to important as in clinical they be to placebo consideration not them some discontinue relief to up a systemic run manner. who may original are need it eliminates label off-label blinded open-label and for this This are order a rolling those receiving their just the and receiving which risk ones symptomatic those both able to decision enroll not symptoms where be of or potentially end in we whether back. studies, make providing very is who in a treatment their currently might and and about coming loved being agonizing off in trial
But being all approved will look with fully our tested believe suffering is We to deliver updates laying Netherton terrible on we to this therapy, a year we we forward people providing foundation possible treatment to and our mission ahead. as the physicians running broad-based continued in disease. where of program throughout that is with first off-label forward generation widest with for conjunction these the the set of syndrome. from be the for up range for monotherapy amendments data the for concurrently, a options the now give studies systemic as With a are clinical of company implemented, QRXXXX truly pivotal our progress XXXX shaping protocol move year treatment
the to lay our product ourselves sell the and to the we front, approved. have plans, support in U.S. our establishment the Western Europe both of once On infrastructure own the to for groundwork commercial continued
effectively given and detail in efficiently that relatively of And that treating the is compact placed number heavily small believe commercial population, product. patient with centers we this strategically affairs. a reps weighted previously, noted limited that physicians As the small sales medical and along treatment regional could infrastructure
year. commercial efforts. these also subsequent throughout to updates We the our own on provide plan calls Supporting activities on
you countries. in us heard past, now that partnerships entered the into from commercial we have X As cover for QRXXXX have XX
the discussions remain expand that unlicensed to in world. will across And the few countries number to we remaining
diligent many commercial patients We continue partnerships into to QRXXXX available that many Netherton countries that as becomes in this thoughtful as possible will ensure approach approved. and systematic as it to believe to entering once is
product amount and As receive our products they partnerships, of for global planned approved U.S. own noted once previously, along approval. a launch these facilitate the also what similar Europe with lay foundation global will to our commercial the the will and pipeline infrastructure also for once Western of launches effectively
company a impact for highly differentiated and unprecedented for advantage material this directly somewhat We represents firmly our have and commercial our size believe will that on of positive perhaps Quoin. future this revenue-generating The is all a a which to partnership incremental global commercial bottom Quoin, ultimately represents fall that network the line global network opportunity profitability. for underappreciated could potential
During our on also previous calls, updated I strategy. our everyone M&A have
to discussed, As and means. portfolio been given our strong via our we focused additional sheet acquisition, expanding capital, on product access balance acutely in-licensing potential have or other
and will us do caution so. unless sense do continue us, really We deal it search execute as opportunities, we not for to but for I remains makes it a the that want company to for a priority to M&A
completed raising public we proceeds a $X.X of offering, gross million. successful week, Last
to the Capital, equity this of half line addition, in which arrangement with earlier be Alumni of able will In $X credit we or an year. access this we year, million entered ELOC second into
credit of With extend equity proceeds the funded our the offering now the of week's from we XXXX will -- proceeds the the of line second last alone, are runway of half further. cash even into and
development another calls, we their IND treatment as an have X a clinical with study Netherton has as letter Finally, noted initiate on product potential previous to for FDA received company may the and our the now proceed syndrome. a of filed
following been the this has of it a clinical the clinicaltrials.gov yesterday, pharmaceutical only of open under conducting actively appears remains website studies an initiated, in As company syndrome yet and review not Netherton study IND. that Quoin
as whilst those studies, either Netherton time further INDs for see noted, filing in time are or pushed about lines completely. to a spoken Furthermore, consistent being have cases have we also either other abandon some of initiating pattern some companies continue we clinical out previously
our significant more the what are we of commercial regulatory be by we treatment for potential the first progress continue opportunity partners and could marketing global the ever to make than approved As on this disease. X excited front, clinical horrendous
over Gordon. I to hand call the will now
